The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Financial headroom and skipping the divi is just fine. As a LTH I actually do not worry too much about this company. A few more contracts will be absorbed i hope as others cant sustain the standstill as well as NEX. Everything will correct itself in due course. A nice sensible share chat here too. Good luck all and relax all good things come to those who wait.
Not sure if i offended any one. Im just saying this and TIFS are the only ones within this section. Now ive always thiught a diverse portfolio reduces risk as one rises one may fall. and this share is an opportunity to so within a fair price. I hear the term ramp and de ramp and its neither of those. As whatever i say is imo. Hence i dont post much. Just seen an exciting share with a half decent chat room (at times). Gla and no offence intended once again.
Hi all. Not a regular poster but have been investing ten years since my mid twenties. I originally purchased this share after grasping the fundamentals and old charts. Just an even 4000 shares. Reason? I wanted to diversify my portfolio and have the potential of that feeling i think aim investers have of multi baggers. Guilty as i sold out for a measly 200 quid profit but just wanted top up something that fell else where in market. I will be back in for 4000 shares 2mw regardless as i see potential. The fundamentals abeit a bit odd add up. And i would be happy at any entry point sub 60 and monitor it. Its too big a company to have 50 trades a day so its all action from here and it eill help diversify my portforlio from pharmaceutical gsk azn unilever etc. Its out on its own snd and will settle. Just needs time and not any gibberish. Must stop n say MTmacs a quality poster and deserves credit. Good luck fellow long term holders.
I do not post much but as a long term holder and pharmacist I do not think pfizer GSK or atrazenica etc have the vacc, it will be from whoever made the virus and it is definalty man made from what I have seen on the frontline.
That being said enjoying the safe haven of pharmaceuticals in the volitile market, while i dabble in a diverse portfolio I never have to worry abot GSK. JATW correct however, GSK is not boring at the moment!
Not one to get into these type of arguments but this harcamone fellow has been sending weird posts in all day. About how we nose dived and where are the buys etc. Only the miracle of finishing blue shut him for a few hours. Let's keep it professional. If it's going up let's all think why (leak, fundamentals,bod,new patents etc etc) and if its going down let's find out why as a team. Not just state 'O it's down'.for me if this drifts it's just cuz its temporary due to people wanting to invest elsewhere. My point is attach a reason to all comments to add value to the board. Rant over. On a more positive note I've been speaking to collegues discussing the results of OXP of the atorvastin and how possible it would be for it to become an over the counter medication (I'm talking about long term plans for company) and it's not impossible or unheard of(in uk)We have seen omeprazole(anti acid drug) and simvastatin (a fellow statin with disadvantages) move from prescription to counter lines. If we can find a price point less than that of a prescription charge we will have a business model beyond scalability. Gosh the more I talk about it the more I want to add. But there's risks involved we all know nothing is easy so this is nor a ramp or deramp. Just trying to bring in a clinical and finacial view to the board and what I think the bod are angling towards. Sorry for the long post guys.
unfortunately I dont think there will be anything new announced until after the presentation. BUT, I feel the presentation may take us to another level. Having read the presentation content several times over, its very exciting. The size of the global market in which we are focusing on is immense. I do feel we will attempt an OTC route on the NSAIDS side as Rx approval will more than likely not be required as the same product is available on the market (just not as good!) Rx approval being granted for our statin would see many of us retire early. This is all speculation and please research all you can as AIM is a tricky horse. I've not been as excited over a share like this since OPTI last year. This may have longer legs as nothing totally new is coming out, just evolution of products. Lets hope for a cracking presentation and nice steady rises so we can soak up shares are we go along. Well done to anyone whos held on. GLA
up to an even 500k shares now. I know a lot of you are looking at the NSAIDs to rocket this company but one should not discount the fact we are working on Atorvastatin. Working in the industry for many years now I have seen the shift onto this statin before my own eyes other simvastatin and a few others, Should we crack a few proven percentile in efficacy we will be a massive company. Happy to wait for more news now. GLA and enjoy the ride
the deal(rns) and steady rise confirms my suspicions on this company, they back on track excuse the pun!
Heard these guys making profit now. Have a feeling might be a slow rise under the radar. This sector can be turbulent but these guys are a good solid comping company again imo
i see good times ahead for this company, I've got property in Hyderabad and spend a lot of time there (when not in Birmingham!) and this company is going places, will be investing for sure, time to bite the bullet